We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Court Ruling Secures GSK’s ‘467 Patent Term on Avodart and Jalyn
The item has been added to your shopping cart.
Court Ruling Secures GSK’s ‘467 Patent Term on Avodart and Jalyn
August 27, 2013
Mylan, Roxane and a handful of other generic drugmakers have not proven “by clear and convincing evidence” that GlaxoSmithKline’s (GSK) ‘467 patent protecting its prostate treatments Avodart and Jalyn are invalid, a federal judge has ruled.